Prospect Profile: Alder Biopharmaceuticals, Inc.


Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Alder Biopharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops and manufactures novel antibody therapeutics to treat autoimmune and inflammatory diseases. As reported in the May 8, 2014 issue of the PharmSource Lead Sheet, Alder raised $80 million in the completion of an IPO.

Corporate Highlights

  • Alder Biopharmaceuticals was incorporated in Delaware in May 2002.
  • Corporate Headquarters: Bothell, Washington – 36,654 square feet of office and laboratory space.
  • As of December 31, 2013, Alder had 77 employees.

Sourcing Opportunities

  • Alder plans to use the net proceeds to fund a planned Phase IIb dose-ranging trial of ALD403, a monoclonal antibody targeting CGRP for prevention of migraine; for preclinical product development activities; and for working capital and other general corporate purposes.
  • The company contracts with a variety of CMOs within North America and Europe for the manufacture of ALD403 and will do the same for future product candidates – Alder anticipates there will be continued interaction with additional CMOs as product candidates advance and as the company looks to expand access to larger production facilities to supply clinical trials and commercialization.
  • Alder relies on third parties to store and distribute supplies for clinical trials.
  • The company relies on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct clinical trials for product candidates.
  • Alder currently has no sales or distribution personnel or infrastructure and only limited marketing capabilities, and may seek a partner.

Business Relationships

  • In November 2009 Alder and BMS entered into a global agreement for the development and commercialization of Clazakizumab, a biologic for the treatment of arthritis. Under the terms, Alder granted to BMS worldwide exclusive rights to develop and commercialize Clazakizumab for potential indications other than cancer, for which Alder retains rights. Alder received an upfront cash payment of $85 million, and may receive potential milestone payments of up to $746 million across a range of indications, and royalties.


Product Candidate Indication Dosage Form Status Next Anticipated Step
Four Preclinical Programs Multiple TBA Preclinical Plans to initiate Phase I for selected candidates in 2015
ALD403 Migraine Parenteral Phase II Plans to initiate Phase IIb in 2014
Clazakizumab (ALD518) Psoriatic Arthritis Parenteral Phase II Phase II data to be presented by the end of 2014
Clazakizumab (ALD518) Rheumatoid Arthritis Parenteral Phase II Follow-on Phase IIb study to be completed in 2014



(In $ thousands) 2013 2012
Revenues 18,796 20,067
R&D Expenditures 31,883 30,669
General & Administrative Expenditures 7,674 7,217
Total Operating Expenses 39,557 37,886
Capital Expenditures 193 1,031


Contact Information

Alder Biopharmaceuticals, Inc. Key Officers
11804 North Creek Parkway South Randall C. Schatzman, PhD, President & CEO
Bothell, WA 98011, USA John A. Latham, PhD, CSO
Phone: 425-205-2900 Mark J. Litton, PhD, CBO & Treasurer
Fax: 425-205-2901 Jeffrey T.L. Smith, MD, SVP, Translational Medicine
Web: Larry Benedict, SVP, Finance

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

More posts by Ryan Worthen